Portfolio Company Updates

Posted: Jan 13, 2020

The MABA Sidecar Fund I has made its first investment, in Cerus Endovascular.

To give the Fund access to a broader range of investment opportunities in which MABA Members are investing, the Fund may invest in opportunities where the investment by MABA Members and/or the Pools was made within six (6) months prior to the closing of the Fund, provided that they satisfy the Fund’s investment rules and, provided further that the same securities are still available from the Presenting Company on the same terms as the MABA Members and/or the Pool(s) invested.

Cerus Endovascular received investment from [ Read more… ]

Posted: Jan 3, 2020

In addition to being active in third-party organized events, for many years MABA also organized its own set of sponsored events titled “1st Pitch Life Science” (1stpitchlifescience.com).  When they began, in 2013, the 1st Pitch events helped establish MABA’s name and brand, while contributing to the deal flow pipeline and increasing our engagement with the local life science early stage ecosystem.

The 1st Pitch events mimicked our investor meetings, and helped educate companies which were not quite ready for funding about the angel investment process, in hopes that that one day they would develop into qualified investment candidates). [ Read more… ]

Posted: Dec 10, 2019

We continue to be very active in our outreach efforts, where we are able to showcase our group, meet new companies, and help seed the deal flow pipeline.  In 2019 we participated in the following events:

• Angel Capital Association – April – in Chicago
• NJ Biopartnering – May
• Ontario Bio – May – web pitching event
• RESI (Redefining Early Stage Investments) – June – Philadelphia
• RESI – September – Boston
• NJEDA – Early Stage Investing in Life Sciences – October – NJ
• J&J JLabs – “Office Hours” – November – NYC
• NJEDA Founders & Funders – [ Read more… ]
  

Posted: Nov 12, 2019

MABA members and the MABA internal investment Pools made two investments in 2019 (that would have qualified for co-investment by the Fund):

• Healionics, a Seattle, Washington-based company, developing a synthetic vascular graft (artificial blood vessel) which remains open to blood flow much longer than conventional vascular grafts.  And,

• Cerus Endovascular, a UK-based company, with manufacturing facilities in California, engaged in the design and development of highly differentiated and proprietary interventional neuroradiology (INR) devices and delivery systems, which it believes will represent the next generation in the minimally invasive treatment of neurovascular diseases, particularly intracranial aneurysms.

Fund investors, [ Read more… ]

Posted: Nov 10, 2019

MABA’s is constantly reviewing new applications for funding, and our yield is fairly consistent.  Of every 100 applications, only 24 are invited to present to our group, while 76 are rejected in pre-screening, for a variety of reasons (which we share with the applicants).  Of the presenting companies, 16, on average, proceed to due diligence, and, of these, two or three receive funding.  These statistics remain fairly consistent, as the number of applications we have reviewed, to-date, exceeds 700.

Posted: September 9, 2021

We hope everyone is staying healthy and safe.

We are happy to announce that the Sidecar Fund has made an investment in New View Surgical (http://newviewsurg.com/), whose novel VisionPort™ System is the first surgeon-controlled, multi-camera laparoscopic visualization system.

New View Surgical (NVS) is a MABA portfolio company, which received multiple investments from our group, the first being in 2017, and included our first internal investment Pool, along with multiple investors.  NVS has made steady progress over the years, securing FDA Clearance for its VisionPort™ System in June of this year.  The current investment is part of a [ Read more… ]